Prostate cancer bone metastases acquire resistance to androgen deprivation via WNT5A-mediated BMP-6 induction

British Journal of Cancer

Volumn 110, Issue 6, 2014, Pages 1634-1644

  Lee, G T ^a,b   Kang, D I ^a   Ha, Y S ^a   Jung, Y S ^a   Chung, J ^b   Min, K ^b   Kim, T H ^c   Moon, K H ^d   Chung, J M ^e   Lee, D H ^f   Kim, W J ^g   Kim, I Y ^a  

^a RUTGERS CANCER INSTITUTE OF NEW JERSEY   (United States)

^b Inje University College of Medicine   (South Korea)

^c Dong A University   (South Korea)

^d University of Ulsan College of Medicine   (South Korea)

^e Kosin University   (South Korea)

^f Ewha Womans University   (South Korea)

^g Chungbuk National University College of Medicine   (South Korea)

Author keywords

BMP 6; bone metastasis; CRPC; WNT5A

Indexed keywords

BETA CATENIN; BONE MORPHOGENETIC PROTEIN 6; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PROSTATE SPECIFIC ANTIGEN; PROTEIN KINASE C; WNT5A PROTEIN;

ADULT; ANDROGEN DEPRIVATION THERAPY; ARTICLE; BONE CELL; BONE METASTASIS; BONE STROMAL CELL; CANCER CELL; CANCER GROWTH; CANCER RESISTANCE; CARCINOGENESIS; CASTRATION RESISTANT PROSTATE CANCER; CELL INTERACTION; CELL PROLIFERATION; COCULTURE; CONTROLLED STUDY; DISEASE COURSE; GENE EXPRESSION; HUMAN; HUMAN CELL; IN VITRO STUDY; MAJOR CLINICAL STUDY; MALE; NONHUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; QUANTITATIVE ANALYSIS; SIGNAL TRANSDUCTION; TISSUE CULTURE;

ADULT; ANDROGEN ANTAGONISTS; ANILIDES; BONE MORPHOGENETIC PROTEIN 6; BONE NEOPLASMS; CELL COMMUNICATION; CELL GROWTH PROCESSES; CELL LINE, TUMOR; HUMANS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; NITRILES; ORCHIECTOMY; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; PROTO-ONCOGENE PROTEINS; RECEPTORS, ANDROGEN; RETROSPECTIVE STUDIES; STROMAL CELLS; TOSYL COMPOUNDS; WNT PROTEINS;

EID: 84896495041     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2014.23     Document Type: Article

References (49)

1. Autzen P, Robson CN, Bjartell A, Malcolm AJ, Johnson MI, Neal DE, Hamdy FC (1998) Bone morphogenetic protein 6 in skeletal metastases from prostate cancer and other common human malignancies. Br J Cancer 78(9): 1219-1223.
2. Barnes J, Anthony CT, Wall N, Steiner MS (1995) Bone morphogenetic protein-6 expression in normal and malignant prostate. World J Urol 13(6): 337-343.
3. Bentley H, Hamdy FC, Hart KA, Seid JM, Williams JL, Johnstone D, Russell RG (1992) Expression of bone morphogenetic proteins in human prostatic adenocarcinoma and benign prostatic hyperplasia. Br J Cancer 66(6): 1159-1163.
4. Blaszczyk N, Masri BA, Mawji NR, Ueda T, McAlinden G, Duncan CP, Sadar MD (2004) Osteoblast-derived factors induce androgen-independent proliferation and expression of prostate-specific antigen in human prostate cancer cells. Clin Cancer Res 10(5): 1860-1869.
5. Bubley GJ, Carducci M, Dahut W, Dawson N, Daliani D, Eisenberger M, Figg WD, Freidlin B, Halabi S, Hudes G, Hussain M, Kaplan R, Myers C, Oh W, Petrylak DP, Reed E, Roth B, Sartor O, Scher H, Simons J, Sinibaldi V, Small EJ, Smith MR, Trump DL, Wilding G et al. (1999) Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group. J Clin Oncol 17(11): 3461-3467.
6. Caubet JF, Tosteson TD, Dong EW, Naylon EM, Whiting GW, Ernstoff MS, Ross SD (1997) Maximum androgen blockade in advanced prostate cancer: a meta-analysis of published randomized controlled trials using nonsteroidal antiandrogens. Urology 49(1): 71-78.
7. Chen G, Shukeir N, Potti A, Sircar K, Aprikian A, Goltzman D, Rabbani SA (2004) Up-regulation of Wnt-1 and beta-catenin production in patients with advanced metastatic prostate carcinoma: potential pathogenetic and prognostic implications. Cancer 101(6): 1345-1356.
8. Clevers H, Nusse R (2012) Wnt/beta-catenin signaling and disease. Cell 149(6): 1192-1205.
9. Crawford ED, Eisenberger MA, McLeod DG, Spaulding JT, Benson R, Dorr FA, Goodman PJ (1989) A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. N Engl J Med 321(7): 419-424.
10. Dai J, Hall CL, Escara-Wilke J, Mizokami A, Keller JM, Keller ET (2008) Prostate cancer induces bone metastasis through Wnt-induced bone morphogenetic protein-dependent and independent mechanisms. Cancer Res 68(14): 5785-5794.
11. Hamdy FC, Autzen P, Robinson MC, Horne CH, Neal DE, Robson CN (1997) Immunolocalization and messenger RNA expression of bone morphogenetic protein-6 in human benign and malignant prostatic tissue. Cancer Res 57(19): 4427-4431.
12. Haudenschild DR, Palmer SM, Moseley TA, You Z, Reddi AH (2004) Bone morphogenetic protein (BMP)-6 signaling and BMP antagonist noggin in prostate cancer. Cancer Res 64(22): 8276-8284.
13. Huang CL, Liu D, Nakano J, Ishikawa S, Kontani K, Yokomise H, Ueno M (2005) Wnt5a expression is associated with the tumor proliferation and the stromal vascular endothelial growth factor-an expression in non-small-cell lung cancer. J Clin Oncol 23(34): 8765-8773.
14. Huggins C (1942) Effect of orchiectomy and irradiation on cancer of the prostate. Ann Surg 115(6): 1192-1200.
15. Ide H, Yoshida T, Matsumoto N, Aoki K, Osada Y, Sugimura T, Terada M (1997) Growth regulation of human prostate cancer cells by bone morphogenetic protein-2. Cancer Res 57(22): 5022-5027.
16. Iozzo RV, Eichstetter I, Danielson KG (1995) Aberrant expression of the growth factor Wnt-5A in human malignancy. Cancer Res 55(16): 3495-3499.
17. Katoh M, Katoh M (2007) WNT signaling pathway and stem cell signaling network. Clin Cancer Res 13(14): 4042-4045.
18. Kim IY, Lee DH, Lee DK, Ahn HJ, Kim MM, Kim SJ, Morton RA (2004) Loss of expression of bone morphogenetic protein receptor type II in human prostate cancer cells. Oncogene 23(46): 7651-7659.
19. Kurayoshi M, Oue N, Yamamoto H, Kishida M, Inoue A, Asahara T, Kikuchi A (2006) Expression of Wnt-5a is correlated with aggressiveness of gastric cancer by stimulating cell migration and invasion. Cancer Res 66(21): 10439-10448.
20. Kwon SJ, Lee GT, Lee JH, Kim WJ, Kim IY (2009) Bone morphogenetic protein-6 induces the expression of inducible nitric oxide synthase in macrophages. Immunology 128(1 Suppl): e758-e765.
21. Lee GT, Kwon SJ, Lee JH, Jeon SS, Jang KT, Choi HY, Kim IY (2010) Induction of interleukin-6 expression by bone morphogenetic protein-6 in macrophages requires both SMAD and p38 signaling pathways. J Biol Chem 285(50): 39401-39408.
22. Lee J, Son MJ, Woolard K, Donin NM, Li A, Cheng CH, Fine HA (2008) Epigenetic-mediated dysfunction of the bone morphogenetic protein pathway inhibits differentiation of glioblastoma-initiating cells. Cancer Cell 13(1): 69-80.
23. Logothetis CJ, Lin SH (2005) Osteoblasts in prostate cancer metastasis to bone. Nat Rev Cancer 5(1): 21-28.
24. Masiello D, Chen SY, Xu Y, Verhoeven MC, Choi E, Hollenberg AN, Balk SP (2004) Recruitment of beta-catenin by wild-type or mutant androgen receptors correlates with ligand-stimulated growth of prostate cancer cells. Mol Endocrinol 18(10): 2388-2401.
25. Massague J (1998) TGF-beta signal transduction. Annu Rev Biochem 67: 753-791.
26. Masuda H, Fukabori Y, Nakano K, Takezawa Y, CSuzuki T, Yamanaka H (2003) Increased expression of bone morphogenetic protein-7 in bone metastatic prostate cancer. Prostate 54(4): 268-274.
27. Messing EM, Manola J, Yao J, Kiernan M, Crawford D, Wilding G, Trump D (2006) Immediate versus deferred androgen deprivation treatment in patients with node-positive prostate cancer after radical prostatectomy and pelvic lymphadenectomy. Lancet Oncol 7(6): 472-479.
28. Miyazono K, Maeda S, Imamura T (2005) BMP receptor signaling: transcriptional targets, regulation of signals, and signaling cross-talk. Cytokine Growth Factor Rev 16(3): 251-263.
29. Noordermeer J, Klingensmith J, Perrimon N, Nusse R (1994) Dishevelled and armadillo act in the wingless signalling pathway in Drosophila. Nature 367(6458): 80-83.
30. Pawlowski JE, Ertel JR, Allen MP, Xu M, Butler C, Wilson EM, Wierman ME (2002) Liganded androgen receptor interaction with beta-catenin: nuclear co-localization and modulation of transcriptional activity in neuronal cells. J Biol Chem 277(23): 20702-20710.
31. Planas Morin J, Morote Robles J (2012) Skeletal complications of ADT: disease burden and treatment options. Asian J Androl 14(5): 670-675.
32. Pukrop R, Krischer M (2005) Changing views about personality disorders: comment about the prospective studies CIC, CLPS, and MSAD. J Pers Disord 19(5): 563-572; discussion 594-566.
33. Rosenzweig BL, Imamura T, Okadome T, Cox GN, Yamashita H, ten Dijke P, Miyazono K (1995) Cloning and characterization of a human type II receptor for bone morphogenetic proteins. Proc Natl Acad Sci USA 92(17): 7632-7636.
34. Saylor PJ, Smith MR (2013) Metabolic complications of androgen deprivation therapy for prostate cancer. J Urol 189(1 Suppl): S34-S42; discussion S43-34.
35. Schellhammer PF (1996) Combined androgen blockade for the treatment of metastatic cancer of the prostate. Urology 47(5): 622-628.
36. Siegel R, Naishadham D, Jemal A (2012) Cancer statistics, 2012. CA Cancer J Clin 62(1): 10-29.
37. Smith MR, Saad F, Coleman R, Shore N, Fizazi K, Tombal B, Goessl C (2012) Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial. Lancet 379(9810): 39-46.
38. Song LN, Herrell R, Byers S, Shah S, Wilson EM, Gelmann EP (2003) Beta-catenin binds to the activation function 2 region of the androgen receptor and modulates the effects of the N-terminal domain and TIF2 on ligand-dependent transcription. Mol Cell Biol 23(5): 1674-1687.
39. Ten Dijke P, Yamashita H, Ichijo H, Franzen P, Laiho M, Miyazono K, Heldin CH (1994) Characterization of type I receptors for transforming growth factor-beta and activin. Science 264(5155): 101-104.
40. Titus MA, Schell MJ, Lih FB, Tomer KB, Mohler JL (2005) Testosterone and dihydrotestosterone tissue levels in recurrent prostate cancer. Clin Cancer Res 11(13): 4653-4657.
41. Truica CI, Byers S, Gelmann EP (2000) Beta-catenin affects androgen receptor transcriptional activity and ligand specificity. Cancer Res 60(17): 4709-4713.
42. Tsukamoto AS, Grosschedl R, Guzman RC, Parslow T, Varmus HE (1988) Expression of the int-1 gene in transgenic mice is associated with mammary gland hyperplasia and adenocarcinomas in male and female mice. Cell 55(4): 619-625.
43. Weeraratna AT, Jiang Y, Hostetter G, Rosenblatt K, Duray P, Bittner M, Trent JM (2002) Wnt5a signaling directly affects cell motility and invasion of metastatic melanoma. Cancer Cell 1(3): 279-288.
44. Yamamoto H, Kitadai Y, Oue N, Ohdan H, Yasui W, Kikuchi A (2009) Laminin gamma2 mediates Wnt5a-induced invasion of gastric cancer cells. Gastroenterology 137(1): 242-252, 252.e1-e6.
45. Yamamoto H, Oue N, Sato A, Hasegawa Y, Matsubara A, Yasui W, Kikuchi A (2010) Wnt5a signaling is involved in the aggressiveness of prostate cancer and expression of metalloproteinase. Oncogene 29(14): 2036-2046.
46. Yang-Snyder J, Miller JR, Brown JD, Lai CJ, Moon RT (1996) A frizzled homolog functions in a vertebrate Wnt signaling pathway. Curr Biol 6(10): 1302-1306.
47. Yang F, Li X, Sharma M, Sasaki CY, Longo DL, Lim B, Sun Z (2002) Linking beta-catenin to androgen-signaling pathway. J Biol Chem 277(13): 11336-11344.
48. Yang X, Chen MW, Terry S, Vacherot F, Bemis DL, Capodice J, Buttyan R (2006) Complex regulation of human androgen receptor expression by Wnt signaling in prostate cancer cells. Oncogene 25(24): 3436-3444.
49. Yu PB, Deng DY, Beppu H, Hong CC, Lai C, Hoyng SA, Bloch KD (2008) Bone morphogenetic protein (BMP) type II receptor is required for BMP-mediated growth arrest and differentiation in pulmonary artery smooth muscle cells. J Biol Chem 283(7): 3877-3888.